Table 2.
Subject secondary characteristics of both the control and treatment group.
| Characteristics | Subcategory | Control Group ≤6 Hours | Treatment Group >6 to ≤24 Hours |
|---|---|---|---|
| Total patients | – | 139 | 327 |
| Chromosomal abnormality (%) | Trisomy 21 | 16 | 9 |
| DiGeorge syndrome | 1 | 5 | |
| Other | 5 | 4 | |
| Comorbidities (%) | Yes | 25 | 29 |
| Diagnosis (%) | TAPVR | 5 | 4 |
| Tricuspid atresia | 0 | <1 | |
| Pulmonary atresia/stenosis | 1 | 2 | |
| Truncus arteriosus | 1 | 2 | |
| ASD/VSD/PDA | 13 | 14 | |
| TOF | 20 | 18 | |
| DTGA ± VSD | 7 | 11 | |
| Coarctation ± VSD | 1 | 1 | |
| Hypoplastic/IAA | 1 | 5 | |
| HLHS | 9 | 6 | |
| AVSD | 12 | 7 | |
| DORV ± VSD | 2 | 2 | |
| LVOTO | 2 | 2 | |
| AVSD/TOF | 0 | <1 | |
| Other/mixed lesions | 26 | 25 | |
| STS-EACTS score (%) | 1–3 | 68 | 64 |
| 4–5 | 32 | 36 |
ASD, atrial septal defect; AVSD, atrioventricular septal defect; DORV, double outlet right ventricle; DTGA, D-transposition of the great arteries; HLHS, hypoplastic left heart syndrome; IAA, interrupted aortic arch; LVOTO, left ventricular outflow tract obstruction; PDA, patent ductus arteriosus; TAPVR, total anomalous pulmonary venous return; TOF, Tetralogy of Fallot; VSD, ventricular septal defect.